Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 13/20 | 0.38 |
| ▸ | CD38 | P28907 | 3/20 | 0.38 |
| ▸ | PLK1 | P53350 | 2/20 | 0.37 |
| ▸ | PLK2 | Q9NYY3 | 2/20 | 0.37 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.37 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.37 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.37 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.37 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.37 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | TAF1 | P21675 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2052920 | 1.00 | NOS2 (0.38) | NOS2CD38PLK1PLK2PLK3 | |
| SCHEMBL2052918 | 0.97 | MEN1 (0.36) | NOS2CD38PLK1PLK2PLK3 | |
| SCHEMBL2052915 | 0.97 | MEN1 (0.36) | NOS2CD38PLK1PLK2PLK3 | |
| SCHEMBL2689534 | 0.78 | NOS2 (0.36) | NOS2CD38 | |
| SCHEMBL2690236 | 0.78 | CD38 (0.35) | NOS2CD38 | |
| SCHEMBL2050138 | 0.77 | BRD4 (0.40) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2050140 | 0.77 | BRD4 (0.40) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2050701 | 0.76 | PLK1 (0.64) | PLK1PLK2PLK3 | |
| SCHEMBL2050698 | 0.76 | PLK1 (0.64) | PLK1PLK2PLK3 | |
| SCHEMBL6840372 | 0.76 | BRD4 (0.39) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516441-B1 | PTERIDINONES AS INHIBITORS OF POLO-LIKE KINASE | ELAN PHARM INC (US) | 2015-01-21 | — | — | EP | disclosed |
| US-20130331376-A1 | INHIBITORS OF POLO-LIKE KINASE | Elan Corporation, Inc. (US) | 2013-12-12 | — | — | US | disclosed |
| US-8541418-B2 | Inhibitors of polo-like kinase | ELAN PHARMACEUTICAL, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| EP-2516441-A1 | PTERIDINONES AS INHIBITORS OF POLO-LIKE KINASE | Elan Pharmaceuticals Inc. (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20110207716-A1 | INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC. | 2011-08-25 | — | — | US | disclosed |
| WO-2011079118-A1 | PTERIDINONES AS INHIBITORS OF POLO-LIKE KINASE | ELAN PHARMACEUTICALS, INC (US) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331376-A1 | INHIBITORS OF POLO-LIKE KINASE | PLK1, POLK, POLR2E | NOS2 3510/4885CD38 3090/4885PLK1 1/4885 |
| US-20110207716-A1 | INHIBITORS OF POLO-LIKE KINASE | PLK1, POLK, POLR2E | NOS2 3510/4885CD38 3090/4885PLK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.